294 related articles for article (PubMed ID: 11712298)
21. Iodine isotope ¹³¹I therapy for toxic nodular goitre: treatment efficacy parameters.
Szumowski P; Rogowski F; Abdelrazek S; Kociura-Sawicka A; Sokolik-Ostasz A
Nucl Med Rev Cent East Eur; 2012 Apr; 15(1):7-13. PubMed ID: 23047567
[TBL] [Abstract][Full Text] [Related]
22. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up in toxic solitary autonomous thyroid nodules treated with radioactive iodine.
Huysmans DA; Corstens FH; Kloppenborg PW
J Nucl Med; 1991 Jan; 32(1):27-30. PubMed ID: 1988632
[TBL] [Abstract][Full Text] [Related]
24. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
[TBL] [Abstract][Full Text] [Related]
25. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.
Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
Thyroid; 1999 May; 9(5):477-81. PubMed ID: 10365679
[TBL] [Abstract][Full Text] [Related]
26. Development of hypothyroidism during long-term follow-up of patients with toxic nodular goitre after radioiodine therapy.
Kahraman D; Keller C; Schneider C; Eschner W; Sudbrock F; Schmidt M; Schicha H; Dietlein M; Kobe C
Clin Endocrinol (Oxf); 2012 Feb; 76(2):297-303. PubMed ID: 21854403
[TBL] [Abstract][Full Text] [Related]
27. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study.
Ceccarelli C; Bencivelli W; Vitti P; Grasso L; Pinchera A
Clin Endocrinol (Oxf); 2005 Mar; 62(3):331-5. PubMed ID: 15730415
[TBL] [Abstract][Full Text] [Related]
28. [Results of the definitive treatment of autonomy in iodine deficiency goiter].
Emrich D; Reinhardt M
Nuklearmedizin; 1989 Feb; 28(1):11-6. PubMed ID: 2710642
[TBL] [Abstract][Full Text] [Related]
29. Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial.
Nielsen VE; Bonnema SJ; Boel-Jørgensen H; Veje A; Hegedüs L
J Clin Endocrinol Metab; 2005 Jan; 90(1):79-83. PubMed ID: 15494456
[TBL] [Abstract][Full Text] [Related]
30. The feasibility of low-dose oral lithium therapy and its effect on thyroidal radioiodine uptake, retention, and hormonal parameters in various subcategories of hyperthyroid patients: a pilot study.
Chouhan A; Abhyankar A; Basu S
Nucl Med Commun; 2016 Jan; 37(1):74-8. PubMed ID: 26465804
[TBL] [Abstract][Full Text] [Related]
31. [Radioiodine 131I therapy of hyperthyroidism on an outpatient basis - safe, effective and economic option].
Jiskra J; Kubinyi J; Telička Z
Vnitr Lek; 2012 Feb; 58(2):94-8. PubMed ID: 22463087
[TBL] [Abstract][Full Text] [Related]
32. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose.
Haase A; Bähre M; Lauer I; Meller B; Richter E
Exp Clin Endocrinol Diabetes; 2000; 108(2):133-7. PubMed ID: 10826521
[TBL] [Abstract][Full Text] [Related]
33. Radioiodine treatment of Plummer's disease.
Moser E
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 4():S63-5. PubMed ID: 9867200
[TBL] [Abstract][Full Text] [Related]
34. [Results of radioiodine therapy in different forms of hyperthyroidism in relation to the planned dosage].
Moser E
Aktuelle Radiol; 1992 Jul; 2(4):179-87. PubMed ID: 1504115
[TBL] [Abstract][Full Text] [Related]
35. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.
Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B
Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334
[TBL] [Abstract][Full Text] [Related]
36. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure].
Urbannek V; Schmidt M; Moka D; Hillger HW; Voth E; Wellner U; Schicha H
Nuklearmedizin; 2000; 39(4):108-12. PubMed ID: 10919161
[TBL] [Abstract][Full Text] [Related]
37. Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy.
Fast S; Hegedüs L; Grupe P; Nielsen VE; Bluhme C; Bastholt L; Bonnema SJ
J Clin Endocrinol Metab; 2010 Aug; 95(8):3719-25. PubMed ID: 20519346
[TBL] [Abstract][Full Text] [Related]
38. What is the best pre-therapeutic dosimetry for successful radioiodine therapy of multifocal autonomy?
Gotthardt M; Rubner C; Bauhofer A; Berce F; Oyen WJ; Goecke J; Pfestroff A; Schlieck A; Corstens FH; Béhé M; Behr TM
Nuklearmedizin; 2006; 45(5):206-12. PubMed ID: 17043731
[TBL] [Abstract][Full Text] [Related]
39. Dose selection for radioiodine therapy of borderline hyperthyroid patients according to thyroid uptake of 99mTc-pertechnetate: applicability to unifocal thyroid autonomy?
Reinhardt MJ; Biermann K; Wissmeyer M; Juengling FD; Brockmann H; von Mallek D; Ezziddin S; Joe AY; Krause TM
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):608-12. PubMed ID: 16541268
[TBL] [Abstract][Full Text] [Related]
40. Single, very low dose (0.03 mg) of recombinant human thyrotropin (rhTSH) effectively increases radioiodine uptake in the I-131 treatment of large nontoxic multinodular goiter.
Mojsak MN; Abdelrazek S; Szumowski P; Rogowski F; Sykała M; Kostecki J; Kociura-Sawicka A; Jurgilewicz D; Myśliwiec J
Nucl Med Rev Cent East Eur; 2016; 19(1):3-11. PubMed ID: 26841373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
